Healthcare · Biotechnology
Price
$4.38
Market Cap
$249.4M
Employees
131
Beta
1.01
Avg Volume
405,161
CEO
Krishna Vaddi
Business Description
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Business History
Price Overview
Last updated: Jun 27, 2026 9:04am (just now)$4.38
+0.28 (+6.83%)
Day Range
$4.03 – $4.38
52-Week Range
$0.75 – $5.54
50-Day MA
$4.35
200-Day MA
$2.73
Volume
3,693,041.00
Analyst Price Targets
Low
$8.00
Consensus
$8.00
High
$8.00
(6 analysts)
Share Structure
Outstanding
78,497,652.00
Float
41,755,976.00
Free Float
53.2%
Normal free float
— 53.2% of shares trade freely, ~46.8% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-3.40
Stock Price: $4.38
EPS (Diluted): -1.29
EPS (Diluted): -1.29
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
3.25
Stock Price: $4.38
Total Equity: $68.64M
Shares: 76,956,194
Total Equity: $68.64M
Shares: 76,956,194
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-3.22
Market Cap: $249.37M
Total Debt: $0.00
Cash: $35.26M
EBITDA: -$97.79M
Total Debt: $0.00
Cash: $35.26M
EBITDA: -$97.79M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$144.4M
Market Cap: $249.37M
Total Debt: $0.00
Cash: $35.26M
Total Debt: $0.00
Cash: $35.26M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
18.38
Stock Price: $4.38
Revenue: $12.14M
Shares: 76,956,194
Revenue: $12.14M
Shares: 76,956,194
EV/Sales (Total value vs revenue — works when P/E can't)
API11.89
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
85.9%
Gross Profit: $10.43M
Revenue: $12.14M
Revenue: $12.14M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-861.3%
Operating Income: -$104.57M
Revenue: $12.14M
Revenue: $12.14M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-819.6%
Net Income: -$99.50M
Revenue: $12.14M
Revenue: $12.14M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-118.2%
Net Income: -$99.50M
Total Equity: $68.64M
Total Equity: $68.64M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-104.3%
Operating Income: -$104.57M
Tax Rate: 0.0%
Equity: $68.64M
Total Debt: $0.00
Cash: $35.26M
Tax Rate: 0.0%
Equity: $68.64M
Total Debt: $0.00
Cash: $35.26M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
1.99
Current Assets: $105.69M
Current Liabilities: $52.99M
Current Liabilities: $52.99M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $68.64M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $68.64M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.16
Revenue: $12.14M
Shares: 76,956,194
Shares: 76,956,194
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$0.89
Total Equity: $68.64M
Shares: 76,956,194
Shares: 76,956,194
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-0.73
Operating CF: -$56.30M
CapEx: -$67,000
Shares: 76,956,194
CapEx: -$67,000
Shares: 76,956,194
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $4.38
Stock Price: $4.38
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$99.50M
Net Income: -$99.50M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares PRLD against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 26, 2026 3:32am (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $7.0M | $12.1M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $1.7M |
| Gross Profit | $0 | $0 | $0 | $7.0M | $10.4M |
| Operating Expenses | $113.7M | $123.5M | $132.3M | $146.7M | $115.0M |
| Operating Income | -$113.7M | -$123.5M | -$132.3M | -$139.7M | -$104.6M |
| Net Income | -$111.7M | -$115.4M | -$121.8M | -$127.2M | -$99.5M |
| EBITDA | -$110.8M | -$114.1M | -$120.7M | -$125.4M | -$97.8M |
| EPS | $-2.33 | $-2.27 | $-2.02 | $-1.68 | $-1.29 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 26, 2026 3:32am (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $31.8M | $30.6M | $25.3M | $12.5M | $35.3M |
| Total Current Assets | $295.1M | $204.4M | $235.6M | $135.9M | $105.7M |
| Total Assets | $305.1M | $220.5M | $277.7M | $175.5M | $141.3M |
| Current Liabilities | $19.2M | $21.7M | $21.8M | $25.6M | $53.0M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $19.2M | $25.1M | $40.6M | $44.1M | $72.7M |
| Total Equity | $285.9M | $195.4M | $237.1M | $131.5M | $68.6M |
| Retained Earnings | -$219.1M | -$334.6M | -$456.4M | -$583.6M | -$683.1M |
Cash Flow (Annual)
Last updated: Jun 26, 2026 3:32am (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$83.5M | -$83.7M | -$107.1M | -$102.9M | -$56.3M |
| Capital Expenditure | -$2.3M | -$3.0M | -$3.5M | $-764,000 | $-67,000 |
| Free Cash Flow | -$85.9M | -$86.7M | -$110.6M | -$103.7M | -$56.4M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$182.4M | -$1.2M | -$5.3M | -$12.8M | $22.0M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 9:04am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$53.3M $53.3M – $53.3M
|
$131.3M $15.9M – $362.0M
|
$100.0M $12.1M – $275.8M
|
$100.0M $12.1M – $275.8M
|
| EBITDA |
$10.7M $10.7M – $10.7M
|
$26.2M $3.2M – $72.4M
|
$20.0M $2.4M – $55.2M
|
$20.0M $2.4M – $55.2M
|
| Net Income |
-$47.2M -$51.2M – -$43.2M
|
-$8.5M -$17.7M – $770,252
|
$21.5M -$3.1M – $70.8M
|
$50.0M -$7.2M – $164.4M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 26, 2026 3:32am (1d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | +73.4% |
| Gross Profit Growth | — | — | — | +49.0% |
| Operating Income Growth | -8.6% | -7.1% | -5.6% | +25.2% |
| Net Income Growth | -3.4% | -5.5% | -4.4% | +21.8% |
| EBITDA Growth | -3.0% | -5.7% | -3.9% | +22.0% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 3:30am (5h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-09 | BAKER BROS. ADVISORS LP | A-Award | 38,000.00 | $3.94 | $149,720 |
| 2026-06-09 | Dorton Katina | A-Award | 38,000.00 | $3.94 | $149,720 |
| 2026-06-09 | Babler Martin | A-Award | 38,000.00 | $3.94 | $149,720 |
| 2026-06-09 | Bonita David P | A-Award | 38,000.00 | $3.94 | $149,720 |
| 2026-06-09 | Sandor Victor | A-Award | 38,000.00 | $3.94 | $149,720 |
| 2026-06-09 | FRIEDMAN PAUL A | A-Award | 38,000.00 | $3.94 | $149,720 |
| 2026-05-01 | Morris Charles Q | A-Award | 450,000.00 | $4.70 | $2.1M |
| 2026-04-27 | RA CAPITAL MANAGEMENT, L.P. | J-Other | 1,407,000.00 | $0.00 | $141 |
| 2026-04-27 | RA CAPITAL MANAGEMENT, L.P. | J-Other | 1,407,000.00 | $0.00 | $141 |
| 2026-04-21 | RA CAPITAL MANAGEMENT, L.P. | 0.00 | $0.00 | $0 | |
| 2026-04-21 | Bonita David P | P-Purchase | 1,689,189.00 | $4.44 | $7.5M |
| 2026-04-21 | Bonita David P | P-Purchase | 1,126,126.00 | $4.44 | $5.0M |
| 2026-04-21 | ORBIMED ADVISORS LLC | P-Purchase | 1,689,189.00 | $4.44 | $7.5M |
| 2026-04-21 | ORBIMED ADVISORS LLC | P-Purchase | 1,126,126.00 | $4.44 | $5.0M |
| 2026-04-21 | BAKER BROS. ADVISORS LP | P-Purchase | 2,137,651.00 | $0.00 | $214 |
| 2026-04-21 | BAKER BROS. ADVISORS LP | P-Purchase | 114,601.00 | $0.00 | $11 |
| 2026-04-15 | Morris Charles Q | 0.00 | $0.00 | $0 | |
| 2026-03-05 | Brusky Sean P. | 0.00 | $0.00 | $0 | |
| 2026-03-05 | Brusky Sean P. | 275,000.00 | $0.00 | $0 | |
| 2026-02-04 | Combs Andrew | A-Award | 230,000.00 | $2.30 | $529,000 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for PRLD — it's generated by the pipeline (
market-narrative step).
No community reviews yet for PRLD.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30